MX2023002318A - Metodo de tratamiento de pacientes con sensibilidad reducida a un inhibidor de bcl-2. - Google Patents
Metodo de tratamiento de pacientes con sensibilidad reducida a un inhibidor de bcl-2.Info
- Publication number
- MX2023002318A MX2023002318A MX2023002318A MX2023002318A MX2023002318A MX 2023002318 A MX2023002318 A MX 2023002318A MX 2023002318 A MX2023002318 A MX 2023002318A MX 2023002318 A MX2023002318 A MX 2023002318A MX 2023002318 A MX2023002318 A MX 2023002318A
- Authority
- MX
- Mexico
- Prior art keywords
- bcl
- inhibitor
- binds
- antibody
- certain embodiments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063072113P | 2020-08-29 | 2020-08-29 | |
| PCT/EP2021/073816 WO2022043538A1 (en) | 2020-08-29 | 2021-08-27 | Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002318A true MX2023002318A (es) | 2023-05-19 |
Family
ID=77821706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002318A MX2023002318A (es) | 2020-08-29 | 2021-08-27 | Metodo de tratamiento de pacientes con sensibilidad reducida a un inhibidor de bcl-2. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240182590A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4204098A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023539493A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230061421A (cg-RX-API-DMAC7.html) |
| CN (2) | CN122351461A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021334165A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3188634A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300996A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002318A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022043538A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| JP2025541170A (ja) * | 2022-12-08 | 2025-12-18 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト | 急性骨髄性白血病のベネトクラクス／低メチル化剤／抗ｃｄ７０剤による治療に対する耐性又は反応性を特定する方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7662387B2 (en) | 2003-02-20 | 2010-02-16 | Seattle Genetics | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| US20080025989A1 (en) * | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| US20100150950A1 (en) | 2006-12-14 | 2010-06-17 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2012071336A1 (en) | 2010-11-23 | 2012-05-31 | Abbott Laboratories | Salts and crystalline forms of an apoptosis-inducing agent |
| US10391168B1 (en) * | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
| WO2017156398A1 (en) | 2016-03-10 | 2017-09-14 | Assia Chemical Industries Ltd. | Solid state forms of venetoclax and processes for preparation of venetoclax |
| CN109563096A (zh) | 2016-06-09 | 2019-04-02 | 雷迪博士实验室有限公司 | 固体形式的维奈托克和用于制备维奈托克的方法 |
| EP3481397A1 (en) | 2016-07-06 | 2019-05-15 | Concert Pharmaceuticals Inc. | Deuterated venetoclax |
| CN107648185A (zh) | 2016-07-25 | 2018-02-02 | 常州爱诺新睿医药技术有限公司 | 一种无定型Venetoclax与药用辅料的固体分散体及其制备方法 |
| US20190177317A1 (en) | 2016-08-12 | 2019-06-13 | Mylan Laboratories Limited | Process for the preparation of venetoclax |
| WO2018069941A2 (en) | 2016-10-14 | 2018-04-19 | Mylan Laboratories Limited | Polymorphic forms of venetoclax |
| EP3333167A1 (en) | 2016-12-09 | 2018-06-13 | LEK Pharmaceuticals d.d. | Solid forms of venetoclax |
| WO2018157803A1 (zh) | 2017-02-28 | 2018-09-07 | 苏州科睿思制药有限公司 | 维奈妥拉的晶型及其制备方法 |
| WO2018167652A1 (en) | 2017-03-13 | 2018-09-20 | Laurus Labs Limited | Process for preparation of amorphous form of venetoclax |
| CN107089981A (zh) | 2017-04-24 | 2017-08-25 | 杭州科耀医药科技有限公司 | 一种BCL‑2抑制剂Venetoclax的合成方法 |
| GB2567613A (en) | 2017-06-16 | 2019-04-24 | Argenx Bvba | Treatment for acute myeloid leukaemia |
| TWI848030B (zh) * | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
-
2021
- 2021-08-27 MX MX2023002318A patent/MX2023002318A/es unknown
- 2021-08-27 IL IL300996A patent/IL300996A/en unknown
- 2021-08-27 EP EP21772989.6A patent/EP4204098A1/en active Pending
- 2021-08-27 KR KR1020237010275A patent/KR20230061421A/ko active Pending
- 2021-08-27 JP JP2023513582A patent/JP2023539493A/ja active Pending
- 2021-08-27 CN CN202610356888.5A patent/CN122351461A/zh active Pending
- 2021-08-27 CA CA3188634A patent/CA3188634A1/en active Pending
- 2021-08-27 AU AU2021334165A patent/AU2021334165A1/en active Pending
- 2021-08-27 CN CN202180053199.2A patent/CN116249519A/zh active Pending
- 2021-08-27 WO PCT/EP2021/073816 patent/WO2022043538A1/en not_active Ceased
-
2023
- 2023-02-27 US US18/175,225 patent/US20240182590A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN122351461A (zh) | 2026-07-10 |
| AU2021334165A1 (en) | 2023-03-02 |
| KR20230061421A (ko) | 2023-05-08 |
| IL300996A (en) | 2023-04-01 |
| CN116249519A (zh) | 2023-06-09 |
| CA3188634A1 (en) | 2022-03-03 |
| US20240182590A1 (en) | 2024-06-06 |
| WO2022043538A1 (en) | 2022-03-03 |
| AU2021334165A8 (en) | 2023-03-16 |
| EP4204098A1 (en) | 2023-07-05 |
| JP2023539493A (ja) | 2023-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021334165A8 (en) | Method of treatment of patients having reduced sensitivity to a BCL-2 inhibitor | |
| MX2021007350A (es) | Terapia combinada de cd70 y venetoclax, un inhibidor de bcl-2, para tratar la leucemia mieloide aguda. | |
| MX2025001714A (es) | Medicamento para el tratamiento y/o prevencion del cancer | |
| Sung et al. | Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells | |
| MX2023002805A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos. | |
| MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| NO20070052L (no) | Fremgangsmate for behandling av multippel sklerose | |
| RU2012117619A (ru) | ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ДЕЙСТВИЮ АНТАГОНИСТА Notch1, С ПОМОЩЬЮ АНТАГОНИСТА Notch3 | |
| PH12012501067A1 (en) | Combination therapy for treating cancer and diagnostic assays for use therein | |
| MX2023002540A (es) | Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma folicular. | |
| CY1113287T1 (el) | Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα | |
| DE60140063D1 (de) | Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper | |
| MX338185B (es) | Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante. | |
| MX2024011278A (es) | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer. | |
| MX2023006793A (es) | Tratamientos conjuntos para tratamiento de cancer her2. | |
| MX2020006171A (es) | Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer. | |
| MX2023014069A (es) | Composiciones y métodos para el tratamiento del cáncer de próstata. | |
| MX2021002241A (es) | Uso de linfocitos infiltrantes de tumor para tratar pacientes con carcinoma de pulmón de células no pequeñas (nsclc) refractario al anticuerpo anti muerte programada 1 (pd-1). | |
| Al-Salool et al. | Emotional distress in head-and-neck cancer patients scheduled for chemoradiation or radiotherapy alone | |
| MX2024002711A (es) | Anticuerpos de receptor de activina tipo-2a (anti-acvr2a) y usos de estos. | |
| CA3242378A1 (en) | Anti-musk antibodies for use in treating neuromuscular disorders | |
| MX2023012766A (es) | Metodo para permitir la infiltracion de las celulas inmunitarias en los tumores. | |
| JP2023539493A5 (cg-RX-API-DMAC7.html) | ||
| NZ594784A (en) | Therapy with CD4 binding peptides and radiation | |
| MX2023015073A (es) | Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la dermatomiositis (dm). |